Literature DB >> 26952844

Quantitative investigation of physical factors contributing to gold nanoparticle-mediated proton dose enhancement.

Jongmin Cho1, Carlos Gonzalez-Lepera, Nivedh Manohar, Matthew Kerr, Sunil Krishnan, Sang Hyun Cho.   

Abstract

Some investigators have shown tumor cell killing enhancement in vitro and tumor regression in mice associated with the loading of gold nanoparticles (GNPs) before proton treatments. Several Monte Carlo (MC) investigations have also demonstrated GNP-mediated proton dose enhancement. However, further studies need to be done to quantify the individual physical factors that contribute to the dose enhancement or cell-kill enhancement (or radiosensitization). Thus, the current study investigated the contributions of particle-induced x-ray emission (PIXE), particle-induced gamma-ray emission (PIGE), Auger and secondary electrons, and activation products towards the total dose enhancement. Specifically, GNP-mediated dose enhancement was measured using strips of radiochromic film that were inserted into vials of cylindrical GNPs, i.e. gold nanorods (GNRs), dispersed in a saline solution (0.3 mg of GNRs/g or 0.03% of GNRs by weight), as well as vials containing water only, before proton irradiation. MC simulations were also performed with the tool for particle simulation code using the film measurement setup. Additionally, a high-purity germanium detector system was used to measure the photon spectrum originating from activation products created from the interaction of protons and spherical GNPs present in a saline solution (20 mg of GNPs/g or 2% of GNPs by weight). The dose enhancement due to PIXE/PIGE recorded on the films in the GNR-loaded saline solution was less than the experimental uncertainty of the film dosimetry (<2%). MC simulations showed highly localized dose enhancement (up to a factor 17) in the immediate vicinity (<100 nm) of GNRs, compared with hypothetical water nanorods (WNRs), mostly due to GNR-originated Auger/secondary electrons; however, the average dose enhancement over the entire GNR-loaded vial was found to be minimal (0.1%). The dose enhancement due to the activation products from GNPs was minimal (<0.1%) as well. In conclusion, under the currently investigated conditions that are considered clinically relevant, PIXE, PIGE, and activation products contribute minimally to GNP/GNR-mediated proton dose enhancement, whereas Auger/secondary electrons contribute significantly but only at short distances (<100 nm) from GNPs/GNRs.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26952844     DOI: 10.1088/0031-9155/61/6/2562

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  5 in total

1.  Development of bimetallic (Zn@Au) nanoparticles as potential PET-imageable radiosensitizers.

Authors:  Jongmin Cho; Min Wang; Carlos Gonzalez-Lepera; Osama Mawlawi; Sang Hyun Cho
Journal:  Med Phys       Date:  2016-08       Impact factor: 4.071

Review 2.  Gold Nanoparticles as a Potent Radiosensitizer: A Transdisciplinary Approach from Physics to Patient.

Authors:  Sébastien Penninckx; Anne-Catherine Heuskin; Carine Michiels; Stéphane Lucas
Journal:  Cancers (Basel)       Date:  2020-07-23       Impact factor: 6.639

3.  Gold Nanoparticle Enhanced Proton Therapy: Monte Carlo Modeling of Reactive Species' Distributions Around a Gold Nanoparticle and the Effects of Nanoparticle Proximity and Clustering.

Authors:  Dylan Peukert; Ivan Kempson; Michael Douglass; Eva Bezak
Journal:  Int J Mol Sci       Date:  2019-09-01       Impact factor: 5.923

4.  Modelling Spatial Scales of Dose Deposition and Radiolysis Products from Gold Nanoparticle Sensitisation of Proton Therapy in A Cell: From Intracellular Structures to Adjacent Cells.

Authors:  Dylan Peukert; Ivan Kempson; Michael Douglass; Eva Bezak
Journal:  Int J Mol Sci       Date:  2020-06-22       Impact factor: 5.923

Review 5.  Particle therapy and nanomedicine: state of art and research perspectives.

Authors:  Sandrine Lacombe; Erika Porcel; Emanuele Scifoni
Journal:  Cancer Nanotechnol       Date:  2017-11-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.